State University of New York (SUNY) Chancellor John B. King Jr. yesterday announced that this technology is a recipient of the latest round of seed funding through the SUNY Technology Accelerator Fund (TAF), which provides grants to faculty inventors and scientists. Potent Melatonin Receptor Ligands are a series of more than 120 novel compounds developed at the University at Buffalo to selectively modulate the MT1 and MT2 melatonin receptors, which play key roles in sleep regulation, circadian rhythms, and numerous physiological processes. These compounds include receptor-specific agonists, partial agonists, antagonists, and inverse agonists with demonstrated receptor-binding activity. Potential applications extend beyond sleep and circadian rhythm disorders to include pain management, depression, hypertension, stroke, inflammatory diseases, autoimmune conditions, and metabolic disorders. The technology has generated in vitro and early in vivo data, is supported by U.S. Provisional Patent Application, and is available for licensing or collaboration.

A new collaborative study reveals how an mRNA-based influenza vaccine reshapes immune responses at the cellular and molecular levels. By tracking germinal-center activity and individual secreted antibody clonotypes for up to six months, researchers uncover how vaccination drives the evolution and diversification of immune responses. The findings offer new insights into how mRNA technology could help address a key challenge in influenza prevention: generating broader antibody responses against a constantly evolving virus.

This Upstate Medical University technology overcomes a major challenge in dengue prevention and treatment: Antibody-Dependent Enhancement (ADE). This phenomenon causes IgG isotype antibodies that recognize dengue virus to enhance infection in individuals with waning or incomplete antiviral immunity. Our technology circumvents this challenge.

This technology is a saliva-based assay to rapidly, accurately, and non-invasively assess flavivirus immunity by measuring various antibody classes present in saliva.

This technology combines PKZ18-22, the most promising analog, with antibiotics from multiple different classes. This synergy provides up to an 8-fold increase in efficacy of aminoglycosides when a small amount of PKZ18-22 is added.